Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on May 1, 2026. The report addresses a critical regulatory event concerning the Company's continued listing on The Nasdaq Stock Market following a 1-for-35 reverse stock split effected on April 30, 2026.
Key Financial Metrics
The filing does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the post-split count of publicly held shares, which stands at approximately 401,226.
Material Changes and Listing Status
On May 1, 2026, the Company received a formal Notice from Nasdaq stating it no longer complies with the minimum 500,000 Publicly Held Shares requirement (Listing Rule 5550(a)(4)). This deficiency is a direct result of the recent reverse stock split. Additionally, the Company remains non-compliant with the minimum $1.00 bid price requirement. Nasdaq has indicated that the Company will remain non-compliant with both requirements until the share count deficiency is cured and the Company subsequently evidences a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management states it is diligently working to satisfy the requirements set forth in the Notice. However, the Company explicitly warns that there can be no assurance it will be able to regain compliance. If the Company fails to meet these requirements, it will be subject to delisting from Nasdaq. The Nasdaq Hearings Panel will consider this matter, and the Company must present its views in writing by May 8, 2026. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of achieving these goals.
Investor Verification Checklist
- Verify the current trading volume and bid price of JAGX to assess the feasibility of meeting the $1.00 bid price requirement.
- Monitor the Company's filings for any proposed capital raising or share issuance plans intended to cure the publicly held shares deficiency.
- Review the Company's response to the Nasdaq Hearings Panel, due by May 8, 2026.
- Check for any subsequent announcements regarding the final decision on the Company's listing status.